JESI, Italy-- (BUSINESS WIRE/AETOSWire): Diatech Pharmacogenetics announced an expansion of its collaboration with Merck ...

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its Emerging Markets & Europe Business Unit (EMEU BU) has achieved a new milestone by being recognized in the ...

Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA ("Merck"). The collaboration aims to improve patient access to RAS ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (“Walden”), a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom ...